Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis

Table 3 Quality assessment for efficacy and safety parameters as per the GRADE approach

No. of studies (design)	Limitation	Inconsistency	Indirectness	Imprecision	Publication bias	Quality	RR (95%CI)
Mortality
Four (RCT)	No serious limitations	Serious inconsistency (I2 = 59%)	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	0.83 (0.57-1.20)
Ventilation
Four (RCT)	No serious limitations	Serious inconsistency (I2 = 77%)	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	0.69 (0.41-1.18)
Composite Mortality and ventilation
Four (RCT)	No serious limitations	Serious inconsistency (I2 = 78%)	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	0.80 (0.58-1.11)
Clinical recovery
Three (RCT)	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	1.10 (1.04-1.16)
Adverse event
Three (RCT)	No serious limitations	Serious inconsistency (I2 = 77%)	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	1.05 (0.86-1.27)
Grade 3 or 4 adverse event
Three (RCT)	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	0.88 (0.79-0.99)
Serious adverse event
Three (RCT)	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	Asymmetric Funnel plot	Moderate	0.75 (0.63-0.89)

CI: Confidence interval; RCT: Randomized controlled trial; RR: Risk ratio.